LexaGene Life Sciences
LexaGene Holdings, Inc. was founded by Dr. Jack Regan in October of 2016. Prior to founding LexaGene Holdings Inc., Dr. Regan developed instruments for bio-warfare surveillance and respiratory pathogen detection. He leveraged his experience with these technologies and other work experiences in both small and large diagnostic companies to form LexaGene and develop a technology to meet unmet needs in underserved markets. To meet this goal, LexaGene developed the MiQLab® System, which is a fully automated sample-to-answer PCR system for rapidly detecting and characterizing microbes. The original market focus of LexaGene was companion animal veterinary bacterial diagnostics. Later in the company’s tenure, based on feedback from people that are in the biopharmaceutical manufacturing industry, management started exploring the use case of the technology to detect broader microbial contaminants that can negatively affect biopharmaceutical manufacturing.
In June 2023, the largest equity holder of LexaGene Holdings, Inc. acquired the assets of the Company and executed a restructuring to form LexaGene Life Sciences. The new Company will carry on the original mission of LexaGene – which is to provide a novel next-generation PCR testing system to industries that are in desperate need of innovation to better run their operations.
To achieve this goal, LexaGene Life Sciences’ new management has retained Dr. Regan as Chief Technology Officer and brought in additional executive leadership to guide the company as it targets the robust biopharmaceutical manufacturing market. As the company gains success in this primary market, it will look to leverage its new technology in other attractive markets, such as food safety testing, water safety testing, and veterinary diagnostics.